{"id":693755,"date":"2010-03-17T13:14:51","date_gmt":"2010-03-17T17:14:51","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=68975"},"modified":"2010-03-17T13:14:51","modified_gmt":"2010-03-17T17:14:51","slug":"acucela-gets-fda-fast-track","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/693755","title":{"rendered":"Acucela Gets FDA Fast Track"},"content":{"rendered":"\n
Biotech<\/a>, Macular Degeneration<\/a>, Drugs<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Acucela and its partner, Japan-based Otsuka Pharmaceutical, said today<\/a> they have received “Fast Track” designation for an application to market a new drug for the “dry” form of age-related macular degeneration. The designation means that the companies will\u00a0 be able to file data on their drug,\u00a0 ACU-4429, as it becomes available, and which makes it possible for the companies to get a faster-than-usual six-month review that is sometimes given to applications to treat serious or life-threatening conditions.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, Macular Degeneration, Drugs Luke Timmerman wrote: Acucela and its partner, Japan-based Otsuka Pharmaceutical, said today they have received “Fast Track” designation for an application to market a new drug for the “dry” form of age-related macular degeneration. The designation means that the companies will\u00a0 be able to file data on their drug,\u00a0 ACU-4429, as […]<\/p>\n","protected":false},"author":843,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-693755","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2UtB","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/693755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/843"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=693755"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/693755\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=693755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=693755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=693755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}